Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)

被引：0

作者：

Robichaux, Jacqulyne P.

Elamin, Yasir Y.

Tan, Zhi

Carter, Brett W.

Zhang, Shuxing

Liu, Shengwu

Li, Shuai

Chen, Ting

Poteete, Alissa

Estrada-Bernal, Adriana

Le, Anh T.

Truini, Anna

Nilsson, Monique B.

Sun, Huiying

Roarty, Emily

Goldberg, Sarah B.

Brahmer, Julie R.

Altan, Mehmet

Lu, Charles

Papadimitrakopoulou, Vassiliki

Politi, Katerina

Doebele, Robert C.

Wong, Kwok-Kin

Heymach, John V.

机构：

[1] University of Texas MD Anderson Cancer Center,Department of Thoracic Head and Neck Medical Oncology

[2] University of Texas MD Anderson Cancer Center,Department of Experimental Therapeutics

[3] University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology

[4] Dana-Farber Cancer Institute,Lowe Center for Thoracic Oncology

[5] University of Colorado Cancer Center,Yale Cancer Center

[6] Yale University School of Medicine,Department of Medicine

[7] Yale University School of Medicine,Sidney Kimmel Comprehensive Cancer Center

[8] Johns Hopkins University,Department of Pathology

[9] Yale University School of Medicine,Laura & Isaac Perlmutter Cancer Center

[10] New York University Langone Medical Center,undefined

来源：

NATURE MEDICINE | 2024年

关键词：

D O I：

10.1038/s41591-024-03178-1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：2694 / 2695

页数：2

共 50 条

[31] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, Simon
Huang, Paul H.
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
[32] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
Joshi, Pooja
Singh, Anita
Bisht, Dheeraj
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
[33] First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC).
Doebele, Robert Charles
Riely, Gregory J.
Spira, Alexander I.
Horn, Leora
Piotrowska, Zofia
Costa, Daniel Botelho
Neal, Joel W.
Zhang, Steven
Reichmann, William
Kerstein, David
Li, Shuanglian
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[34] Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
Li, Kelly
Bosdet, Ian
Yip, Stephen
Ho, Cheryl
Laskin, Janessa
Melosky, Barbara
Wang, Ying
Sun, Sophie
CURRENT ONCOLOGY, 2023, 30 (08) : 7099 - 7111
[35] EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992
James F. Spicer
Sarah M. Rudman
Targeted Oncology, 2010, 5 : 245 - 255
[36] EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992
Spicer, James F.
Rudman, Sarah M.
TARGETED ONCOLOGY, 2010, 5 (04) : 245 - 255
[37] Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China
Yating Hou
Xingyang Xue
Zhuoyun Zhang
Dahai Mai
Wei Luo
Mingyu Zhou
Zichuan Liu
Yisheng Huang
BMC Cancer, 25 (1)
[38] Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates
Meador, Catherine B.
Sequist, Lecia, V
Piotrowska, Zofia
CANCER DISCOVERY, 2021, 11 (09) : 2145 - 2157
[39] Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Byeon, Seonggyu
Kim, Youjin
Lim, Sung Won
Cho, Jang Ho
Park, Sehoon
Lee, Jiyun
Sun, Jong-Mu
Choi, Yoon-La
Lee, Se-Hoon
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung-Ju
CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 623 - 631
[40] Exclusive mutation in EGFR, HER2, and KRAS, and synchronous methylation of non-small cell lung cancer
Suzuki, Makoto
Shigematsu, Hisayuki
Iizasa, Toshihiko
Minna, John D.
Fujisawa, Takehiko
Gazdar, Adi F.
CANCER RESEARCH, 2006, 66 (08)

← 1 2 3 4 5 →